Publications by authors named "Dan C Henry"
Background: Treatment guidelines for acute bacterial rhinosinusitis (ABRS) recommend 10 to 14 days of therapy with high-dose amoxicillin, amoxicillin/clavulanate, cefdinir, cefpodoxime, cefuroxime, a macrolide, or a newer fluoroquinolone, among other agents.
Objective: This study compared the clinical efficacy and tolerability of cefdinir and levofloxacin in patients with a diagnosis of acute rhinosinusitis of presumed bacterial origin.
Methods: In this multicenter, double-blind, noninferiority study, ambulatory adult patients who had signs and symptoms for >7 to 21 days before the screening visit and radiographic findings consistent with acute rhinosinusitis were randomized to receive cefdinir 600 mg or levofloxacin 500 mg, each once daily for 10 days.
Objectives: To compare the efficacy and safety of ciprofloxacin 0.3%/dexamethasone 0.1% (CIP/DEX) otic suspension with that of neomycin 0.
View Article and Find Full Text PDFArticle Synopsis
- A study compared the effectiveness and safety of two different azithromycin regimens (for 3 days and 6 days) against amoxicillin-clavulanate in treating adults with acute bacterial sinusitis.
- The success rates of treatment were similar across all regimens, with clinical success at the end of therapy being around 88.8% for AZM-3, 89.3% for AZM-6, and 84.9% for AMC.
- However, amoxicillin-clavulanate had a higher rate of treatment-related adverse events (51.1%) compared to azithromycin (31.1% for AZM-3 and 37.6% for AZM-6
Background: Trimethoprim/sulfamethoxazole (TMP/SMX) is currently the first choice for empiric therapy of acute uncomplicated urinary tract infection (UTI) in women. In areas where resistance to TMP/SMX is known to be high, ciprofloxacin and other fluoroquinolones are recommended as first-line choices for the empiric therapy of UTI.
Objective: This study compared the efficacy and safety profile of once-daily extended-release ciprofloxacin 500 mg (referred to hereafter as ciprofloxacin QD) with those of conventional ciprofloxacin 250 mg BID, each administered orally for 3 days, in the treatment of uncomplicated UTI in women.